13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001937964
Total reported value
$541.9M
$541.9M
35 檔
21.5%
According to the latest 13F quarterly dataset, Artia Global Partners LP managed an equity portfolio of $541.9M at the end of Q4 2024, spanning 35 distinct U.S. exchange-listed positions.
Artia Global Partners LP executed strategic sector rebalancing during Q4 2024, establishing 10 new positions while fully exiting 19 holdings and trimming 3 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 13.83% | — | -39.33% | |
| 2 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 7.94% | -0.46% | EXIT | |
| 3 | ✓ | Merus N V | Stock-Other | 6.97% | — | +478.56% | |
| 4 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 6.56% | — | +1.48% | |
| 5 | ACLXGBX | Arcellx Inc | Stock-Other | 6.30% | — | — | |
| 6 | NUVL | Nuvalent Inc-a | Stock-Other | 5.71% | +0.01% | +1221.79% | |
| 7 | PCVX | Vaxcyte Inc | Stock-Other | 4.75% | — | +112.78% | |
| 8 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 4.74% | — | +61.14% | |
| 9 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 4.47% | — | — | |
| 10 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 4.44% | +3.98% | +196.39% | |
| 11 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.24% | — | +71.83% | |
| 12 | INSM | Insmed Inc | Stock-Healthcare | 4.14% | -18.15% | +217.23% | |
| 13 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 4.05% | +0.04% | +136.14% | |
| 14 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 3.22% | +2.92% | NEW | |
| 15 | JANX | Janux Therapeutics Inc | Stock-Other | 3.12% | — | — | |
| 16 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.49% | +0.74% | -25.28% | |
| 17 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.20% | — | — | |
| 18 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.30% | +0.12% | -83.06% | |
| 19 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.00% | — | — | |
| 20 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.84% | — | — | |
| 21 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.83% | +0.52% | — | |
| 22 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 23 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.69% | — | — | |
| 24 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.59% | — | — | |
| 25 | EYPT | Eyepoint Inc | Stock-Other | 0.58% | +0.04% | +38.64% | |
| 26 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.56% | -0.04% | — | |
| 27 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.53% | — | — | |
| 28 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.50% | -0.08% | — | |
| 29 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.48% | — | — | |
| 30 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.48% | +0.33% | — | |
| 31 | CRL | Charles River Laboratories | Stock-Healthcare | 0.42% | — | — | |
| 32 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.41% | — | — | |
| 33 | ASND | Ascendis Pharma A/S | Stock-Other | 0.37% | -0.81% | EXIT | |
| 34 | ANNX | Annexon Inc | Stock-Other | 0.32% | — | — | |
| 35 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.27% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx Inc | +6.3% | NEW | New buy |
| 2 | ✓ | Merus N V | +5.9% | +478.56% | Add |
| 3 | NUVL | Nuvalent Inc-a | +5.3% | +1221.79% | Add |
| 4 | SLNOEUR | Soleno Therapeutics Inc | +4.2% | +80.17% | Add |
| 5 | RVMD | Revolution Medicines Inc | +3.3% | +196.39% | Add |
| 6 | XBI | Ss Spdr S&p Biotech ETF | +3.2% | NEW | New buy |
| 7 | JANX | Janux Therapeutics Inc | +3.1% | NEW | New buy |
| 8 | INSM | Insmed Inc | +3.1% | +217.23% | Add |
| 9 | VRNA | Verona Pharma PLC - Adr | +3.1% | +71.83% | Add |
| 10 | PTGX | Protagonist Therapeutics Inc | +2.5% | +136.14% | Add |
| 11 | PCVX | Vaxcyte Inc | +2.4% | +112.78% | Add |
| 12 | ITCIEUR | Intra-cellular Therapies Inc | +2.2% | +1.48% | Add |
| 13 | ALNY | Alnylam Pharmaceuticals Inc | +2.1% | +61.14% | Add |
| 14 | RYTM | Rhythm Pharmaceuticals Inc | +1% | NEW | New buy |
| 15 | ELVN | Enliven Therapeutics Inc | +0.8% | NEW | New buy |
| 16 | NBIX | Neurocrine Biosciences Inc | +0.8% | — | Unchanged |
| 17 | VRDN | Viridian Therapeutics Inc | +0.7% | NEW | New buy |
| 18 | TGTX | Tg Therapeutics Inc | +0.6% | NEW | New buy |
| 19 | EWTX | Edgewise Therapeutics Inc | +0.5% | NEW | New buy |
| 20 | AZNN | Astrazeneca Plc-spons Adr | +0.4% | — | Unchanged |
| 21 | TARS | Tarsus Pharmaceuticals Inc | +0.4% | NEW | New buy |
| 22 | TECX | Tectonic Therapeutic Inc | +0.3% | NEW | New buy |
| 23 | ARGX | Argenx Se - Adr | +0.3% | -25.28% | Trim |
| 24 | NAMS | NewAmsterdam Pharma Company N.V. | +0.3% | — | Unchanged |
| 25 | EYPT | Eyepoint Inc | +0.2% | +38.64% | Add |
| 26 | SWTXUSD | Springworks Therapeutics Inc | +0.2% | — | Unchanged |
| 27 | CRNX | Crinetics Pharmaceuticals In | +0.2% | — | Unchanged |
| 28 | 260 | Centessa Pharmaceuticals-adr | +0.1% | — | Unchanged |
| 29 | XENE | Xenon Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 30 | CRL | Charles River Laboratories | +0.1% | — | Unchanged |
| 31 | ASND | Ascendis Pharma A/S | +0.1% | — | Unchanged |
| 32 | MREO | Mereo Biopharma Group Pl-adr | +0.1% | — | Unchanged |
| 33 | ANNX | Annexon Inc | 0% | — | Unchanged |
| 34 | QTTB | Q32 Bio Inc | -0.1% | EXIT | Sold out |
| 35 | MDGL | Madrigal Pharmaceuticals Inc | -0.1% | EXIT | Sold out |
| 36 | SMMT | Summit Therapeutics Inc | -0.1% | EXIT | Sold out |
| 37 | ✓ | Acelyrin Inc | -0.1% | EXIT | Sold out |
| 38 | LRMR | Larimar Therapeutics Inc | -0.2% | EXIT | Sold out |
| 39 | IRON | Disc Medicine Inc | -0.2% | EXIT | Sold out |
| 40 | SNDX | Syndax Pharmaceuticals Inc | -0.3% | EXIT | Sold out |
| 41 | ALEC | Alector Inc | -0.3% | EXIT | Sold out |
| 42 | SLN | Silence Therapeutics Plc-adr | -0.3% | EXIT | Sold out |
| 43 | CRBP | Corbus Pharmaceuticals Holdi | -0.3% | EXIT | Sold out |
| 44 | KURA | Kura Oncology Inc | -0.3% | EXIT | Sold out |
| 45 | KROS | Keros Therapeutics Inc | -0.3% | EXIT | Sold out |
| 46 | IONS | Ionis Pharmaceuticals Inc | -0.3% | EXIT | Sold out |
| 47 | IDYA | Ideaya Biosciences Inc | -0.5% | EXIT | Sold out |
| 48 | CLDX | Celldex Therapeutics Inc | -0.7% | EXIT | Sold out |
| 49 | DYN | Dyne Therapeutics Inc | -1.2% | EXIT | Sold out |
| 50 | AXSM | Axsome Therapeutics Inc | -2.2% | EXIT | Sold out |
According to official SEC Form 13F filings, Artia Global Partners LP reported a total U.S. public equity portfolio value of $541.9M across 35 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NVO, SLNOEUR, MERUS N V) accounted for 21.5% of total reported equity market value during Q4 2024.
Top New Position Initiated
ACLXGBX
市值: $17.6M
Top Position Liquidated / Trimmed
LLY
前期市值: $95.3M
During Q4 2024, Artia Global Partners LP's top holdings by market value included NVO (13.8%)、SLNOEUR (7.9%)、MERUS N V (7.0%). The largest single position, NVO, represented 13.8% of total portfolio value.
In Q4 2024, Artia Global Partners LP made 43 total portfolio adjustments, initiating 10 new buys, adding to 11 positions, trimming 3 holdings, and fully liquidating 19 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.